Search Results

Santhera Pharmaceuticals is pleased to note the launch of AGAMREE® for the treatment of Duchenne muscular dystrophy in the United States by Catalyst Pharmaceuticals, Inc., the Company’s commercialization partner for North America.

Santhera Pharmaceuticals announces the publication of its Annual Report 2023 with fully audited results for the year ended December 31, 2023.

Santhera Pharmaceuticals published the invitation to its Annual General Meeting, which will be held on June 18, 2024, at 10:00 CEST at Haus der Wirtschaft, Hardstrasse 1, 4133 Pratteln, Switzerland.

Catalyst Pharmaceuticals, Inc. today announced that the peer-reviewed journal Neurology has published Santhera Pharmaceutical’s (“Santhera”) study titled “ Efficacy and Safety of Vamorolone Over 48 Weeks in Boys With Duchenne Muscular Dystrophy”.

Santhera Pharmaceuticals announces that it has entered into committed financing arrangements that, when consummated, will provide Santhera with gross funding totaling approximately CHF 69 million to drive growth, repay maturing bonds and extend cash runway through to the first half of 2026, at which point Santhera expects to be cash flow break-even.

Catalyst Pharmaceuticals, Inc. (“Catalyst” or “Company”) (Nasdaq: CPRX) today reported that Santhera Pharmaceuticals (“Santhera”) has obtained U.S. Food and Drug Administration (“FDA”) approval for AGAMREE® (vamorolone) oral suspension 40 mg/mL for use in treating Duchenne Muscular Dystrophy (“DMD”) in patients aged two years and older.